Call Us: 1.800.873.5297

By

Takata Modifies Chemical Formula of Propellants in Airbags

The Wall Street Journal reports that Takata has modified the chemical formula of propellants inside their airbags after some were recalled for exploding too forcefully and causing injuries to drivers and passengers. However, a company spokesperson said that the modifications are not in response to any design flaws in previous airbags, nor are they a […]

By

TVM Lawsuit Update: Boston Scientific Ordered by Jury to Pay $26.7 Million In Damages

The Boston Journal reports that Boston Scientific, manufacturer of transvaginal mesh devices, has been ordered by a jury to pay four women a total of $26.7 million in compensatory damages. After an eight-day trial, the jury deliberated and found Boston Scientific liable for selling faulty transvaginal mesh devices. This was one of the first federal […]

By

Global Settlement Reached in Stryker Hip Implant Litigation (MDL 2441)

Yahoo! News reports that a global settlement has been reached in the litigation involving Stryker’s Rejuvenate and ABG II modular  hip implants. Stryker has agreed to provide a base payment of $300,000 to patients who received the Stryker implants at issue and underwent revision surgery to remove and/or replace the devices before or by November […]

By

Takata Faces Potential Inquiry by United States Justice Department regarding Airbags

The New York Times reports that three senators are requesting a “criminal investigation of the airbag manufacturer, Takata, after two former employees reported that the company tested the airbags over a decade ago and found no signs of defects, yet erased computer files containing data and threw away tested airbags.” Senator Richard Blumenthal of Connecticut […]

By

FDA Advisory Committee Supports New Anticoagulant Drug Savaysa® (Edoxaban)

Forbes reports that the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Savaysa® (Edoxaban), an anticoagulant manufactured by Daiichi Sankyo. If approved by the FDA, this drug will become the fourth novel oral anticoagulant (NOAC) to receive FDA approval alongside Pradaxa, Xarelto, and Eliquis. Although the panel clearly supported […]

By

Defense Verdict in First DePuy Pinnacle™ MDL Bellwether Case

Reuters reports that Johnson & Johnson was found not liable by a jury in the first federal  bellwether trial case in Texas over whether Pinnacle™ hip implants manufactured by DePuy were defective. The first bellwether trial in the DePuy Pinnacle™ Multidistrict Litigation (In Re: DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation, MDL No. […]

By

Actos® MDL Update: $9B Jury Verdict Against Takeda & Eli Lilly in First Actos MDL Trial Reduced to $36.8M

Law360 reports that the jury verdict of $9 billion in punitive damages against Takeda and Eli Lilly over the type II diabetes drug, Actos®, in the first federal trial has been reduced to $36.8 million. In particular, Judge Doherty ruled that although the verdict was not unreasonable, the jury “should bow” to the Constitution’s due […]

By

Automakers Issue Recalls for Defective Airbags Worldwide

According to Bloomberg News, the Japanese-based company, Takata Corporation, has supplied allegedly defective airbags to automakers. The airbags deploy under too much force, spraying metal shrapnel in the air and at vehicle occupants. At least four deaths and over 30 injuries in the United States have been linked to the safety device’s defective deployment. The […]

By

Toyota Issues Another Recall for Over 1 Million Vehicles Worldwide

Law360 reports that Toyota Motor Corp. will recall 1.67 million vehicles worldwide after identifying defects that make the cars unsafe to drive without repairs, including faulty brakes and fuel components. A Toyota spokesperson said that the recall will affect over 1 million vehicles in Japan, as well as another 615,000 in other areas of the […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.